FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
Highleyman
L
L
D015075:2-Aminopurine / Q000627:therapeutic use*; D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D017277:Drug Approval; D000077595:Famciclovir; D019247:HIV Wasting Syndrome / Q000188:drug therapy*; D006561:Herpes Simplex / Q000188:drug therapy*; D006562:Herpes Zoster / Q000188:drug therapy; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy; D013792:Thalidomide / Q000627:therapeutic use*; D013873:Thionucleotides / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D007917:Leprostatic Agents; D013873:Thionucleotides; D015075:2-Aminopurine; D013792:Thalidomide; D000077595:Famciclovir; C091346:fomivirsen